Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Bill Gates reveals the 5 things he wish he had heard in his youth
Pick up a refurbished MacBook Air for $345.99
Joe Rogan raises alarming 'red flags' claiming China infiltrates US via manipulative student exchange tactics, fans label him 'politician'
The M1 MacBook Air is back at its all-time low price
When is the Anime Girl Coming Back to Only Up?
Roblox 101: How To Make Real Money From Your Video Games
European Parliament votes on curbs for ChatGPT and other AI
Powerful earthquake kills at least 296 in Morocco, govt says